User login
The theme of this year’s annual meeting of the American Society of Clinical Oncology is Delivering Discoveries: Expanding the Reach of Precision Medicine. Of the more than 2,500 abstracts accepted for presentation,
• 5000, A randomized, phase 3 trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high-risk prostate cancer: Results of SPCG-13 trial.
• 5002, A randomized study of finite abiraterone acetate (AA) plus leuprolide (LHRHa) versus LHRHa in biochemically recurrent nonmetastatic hormone-naïve prostate cancer (M0HNPC).
• 5004, The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E).
• LBA5005, Overall survival between African American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC).
• 5006, Results of PROSPECT: A randomized, phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.
• 5007, KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
• 5020, Microsatellite instability in prostate cancer and response to immune checkpoint blockade.
• 5012, Phenotypic and genomic characterization of CTCs as a biomarker for prediction of Veliparib therapy benefit in mCRPC.
• 5022, Radium-223 retreatment in an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases: 2-year follow-up.
• 5032, Association of metastasis-free survival (MFS) and overall survival (OS) in nonmetastatic castration-resistant prostate cancer (nmCRPC).
• 5040, Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Interim results of a phase 2 trial.
Dr. Walter M. Stadler, is the Fred C. Buffett Professor of Medicine and Surgery; deputy director of the University of Chicago Medicine Comprehensive Cancer Center; associate dean for clinical research; chief, section of hematology/oncology; and director, genitourinary oncology program at the University of Chicago.
The theme of this year’s annual meeting of the American Society of Clinical Oncology is Delivering Discoveries: Expanding the Reach of Precision Medicine. Of the more than 2,500 abstracts accepted for presentation,
• 5000, A randomized, phase 3 trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high-risk prostate cancer: Results of SPCG-13 trial.
• 5002, A randomized study of finite abiraterone acetate (AA) plus leuprolide (LHRHa) versus LHRHa in biochemically recurrent nonmetastatic hormone-naïve prostate cancer (M0HNPC).
• 5004, The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E).
• LBA5005, Overall survival between African American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC).
• 5006, Results of PROSPECT: A randomized, phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.
• 5007, KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
• 5020, Microsatellite instability in prostate cancer and response to immune checkpoint blockade.
• 5012, Phenotypic and genomic characterization of CTCs as a biomarker for prediction of Veliparib therapy benefit in mCRPC.
• 5022, Radium-223 retreatment in an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases: 2-year follow-up.
• 5032, Association of metastasis-free survival (MFS) and overall survival (OS) in nonmetastatic castration-resistant prostate cancer (nmCRPC).
• 5040, Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Interim results of a phase 2 trial.
Dr. Walter M. Stadler, is the Fred C. Buffett Professor of Medicine and Surgery; deputy director of the University of Chicago Medicine Comprehensive Cancer Center; associate dean for clinical research; chief, section of hematology/oncology; and director, genitourinary oncology program at the University of Chicago.
The theme of this year’s annual meeting of the American Society of Clinical Oncology is Delivering Discoveries: Expanding the Reach of Precision Medicine. Of the more than 2,500 abstracts accepted for presentation,
• 5000, A randomized, phase 3 trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high-risk prostate cancer: Results of SPCG-13 trial.
• 5002, A randomized study of finite abiraterone acetate (AA) plus leuprolide (LHRHa) versus LHRHa in biochemically recurrent nonmetastatic hormone-naïve prostate cancer (M0HNPC).
• 5004, The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E).
• LBA5005, Overall survival between African American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC).
• 5006, Results of PROSPECT: A randomized, phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.
• 5007, KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
• 5020, Microsatellite instability in prostate cancer and response to immune checkpoint blockade.
• 5012, Phenotypic and genomic characterization of CTCs as a biomarker for prediction of Veliparib therapy benefit in mCRPC.
• 5022, Radium-223 retreatment in an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases: 2-year follow-up.
• 5032, Association of metastasis-free survival (MFS) and overall survival (OS) in nonmetastatic castration-resistant prostate cancer (nmCRPC).
• 5040, Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Interim results of a phase 2 trial.
Dr. Walter M. Stadler, is the Fred C. Buffett Professor of Medicine and Surgery; deputy director of the University of Chicago Medicine Comprehensive Cancer Center; associate dean for clinical research; chief, section of hematology/oncology; and director, genitourinary oncology program at the University of Chicago.